BUZZ - Wendy's shares rise as Q3 results beat expectations and the company rejects a takeover offer led by Trian
路透社2026/11/05 14:22November 5 - ** Fast food chain Wendy's WEN.O saw its share price rise about 2% in pre-market trading, to $7.81
** The company said its independent committee has rejected (link) a $1.4 billion privatization acquisition offer (link) from billionaire Nelson Peltz’s Trian Fund Management.
** In October, Peltz and several partners made an offer to acquire WEN, believing that the struggling fast-food chain needs restructuring, and that such restructuring can best be achieved out of public view
** After rejecting the $7.35 per share acquisition proposal led by Trian, Wendy’s adopted a one-year shareholder rights plan, which is automatically triggered if any holding reaches 15%
** Trian declined Reuters’ request for comment
** The company also released its third quarter earnings report
** The report showed third quarter revenue of $547 million, beating analyst expectations of $530.5 million—data compiled by London Stock Exchange Group (LSEG)
** Quarterly adjusted earnings per share were 13 cents, above market expectations of 9 cents
** As of the previous trading day’s close, WEN is down about 8% year-to-date
(To assist non-English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or lack essential context, Reuters does not guarantee the accuracy of these texts—they are provided solely for readers' convenience. Reuters assumes no responsibility for any loss or damage resulting from the use of automated translations.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Crypto prices
More
